Furthermore, we discovered other target genes and drug repurposing candidates for depression, the efficacies of which are supported by published evidence; for example, muromanab, which targets CD3D/CD247 [113,114], and taurine, which targets GABBR1 [115,116]. Here, CD247 is linked to depressive symptom measurement.